Abstract LB-246: TIGAR Amplification Promotes Glutamine Addition in the Progression of Esophageal Squamous Cell Carcinoma

Jiahui Chu,Mingming Shao,Jiang Chang,Qionghua Cui,Linna Peng,Yingying Luo,Wen Tan,Chen Wu,Dongxin Lin
DOI: https://doi.org/10.1158/1538-7445.am2018-lb-246
IF: 11.2
2018-01-01
Cancer Research
Abstract:Abstract BACKGROUND: Our previous whole-genome sequencing in esophageal squamous-cell carcinoma (ESCC) has identified 23 focal regions with recurrent gain of copy number that contain 1591 genes. Further integrative analysis of copy number alterations with mRNA expression levels showed 141 copy-number amplified genes that had higher mRNA levels, suggesting an important role of these genes in ESCC. This study was to investigate the functional roles of these genes and their potential as biomarkers and therapeutic targets for ESCC. METHODS: An siRNA library was used to knock down all these 141 genes in ESCC cells and change of the malignant phenotype of these cancer cells was examined by using a high-throughput imaging method and in vitro proliferation and colony formation assays. The acting mechanism of the interest genes on malignant phenotypes of cells was explored using biochemical and molecular biological assays. We also examined the effect of the amplified genes on sensitivity of cancer cells to anticancer agents in vitro and in vivo in mice. RESULTS: We found that, among the 141 examined genes, TIGAR was the top one influencing ESCC cell proliferation in vitro and in vivo in xenografts. We confirmed that TIGAR can inhibit glycolysis and divert the carbon flux into the PPP to produce ribose-5-phosphate (R5P) for nuclear synthesis in cells. Overexpression of TIGAR may activate AMPKα that regulated mRNA translation and glutamine-dependent mitochondrial metabolism to maintain energy balance in cells with a reduced glycolysis ability, which was responsible for energy production under normal conditions. We found that ESCC cells overexpressing TIGAR had an addiction to glutamine metabolism and were sensitive to glutaminase inhibitors. Glutamine restriction or glutaminase inhibitors had a synergistic effect with chemotherapy drugs, such as DDP and 5-Fu, on killing of ESCC cells, suggesting that glutaminase inhibitors may be used as adjuvant agents for treatment of ESCC with TIGAR amplification. CONCLUSION: These results suggest that amplification or overexpression of TIGAR may prevent ESCC cells from killing by anticancer drugs and thus may represent a therapeutic target for ESCC. Citation Format: Jiahui Chu, Mingming Shao, Jiang Chang, Qionghua Cui, Linna Peng, Yingying Luo, Wen Tan, Chen Wu, Dongxin Lin. TIGAR amplification promotes glutamine addition in the progression of esophageal squamous cell carcinoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr LB-246.
What problem does this paper attempt to address?